TRIPS Flexibilities and Access to Medicines: A European Approach

Guide | 13 December, 2018 | Download PDF 

Medicines are an essential element in improving our health and well-being, and affordability is critical to making universal health coverage a reality. In the European Union EU, sky-rocketing prices of new, patented medicines are straining public health budgets and jeopardising access.

Dutch Government Not Living up to Promises to Make New Medicines Affordable

Press Release | 6 December, 2018 | Download PDF

Netherlands leads EU on commitments to improving transparency and affordability of medicines, but meaningful action still lacking

AMSTERDAM—New research by Health Action International (HAI) has found that the Dutch government is failing to live up to its commitments to tackle the astronomical prices of new medicines and address the lack of transparency in the medicine pricing system.

New and Affordable Medicines in the Netherlands: Tracing the Dutch Government’s Policy Commitments and Actions

Report | 6 December, 2018 | Download PDF

Similar to its European Union (EU) neighbours, the Netherlands struggles to afford the ever-increasing prices for new medicines. One of the first signals of a turning tide came in 2015 when nivolumab was marketed at a total projected cost of €200 million per year to treat patients in the Netherlands with advanced stage,

HAI and Snakebite Programme Partner, James Ashe Antivenom Trust, Applaud Government Action on Antivenom at Bio-Ken Snakebite Symposium

by SABRINA HENNECKE, Assistant Programme Officer (Snakebite)

Take away the snakes and the sunburn, and Watamu, Kenya truly does look like paradise. Endless white sand cozies up to a sparkling blue ocean, surrounded by lush greenery and sprinkled with towering coconut palms. Nothing could be more different from my drafty home in cold,

Access a Major Obstacle for One in Two People Using Insulin to Manage Type 2 Diabetes

Press Release | 21 November, 2018 | Download PDF

A paper published in The Lancet Diabetes and Endocrinology estimates that, between 2018 and 2030, the number of people with type 2 diabetes using insulin will rise to 79 million. But without improved availability and affordability, over half of those will face challenges in accessing this life-saving medicine.

Civil Society Position on European Commission Proposal for the Introduction of an SPC Manufacturing Waiver

Joint Statement | 6 November, 2018 | Download PDF

As civil society organisations working on access to medicines and public health, we wish to contribute to the ongoing discussions on the European Commission proposal for the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver.

European health authorities have a duty to establish a framework guaranteeing access to effective,

Regulating Off-label Use of Medicines in Europe

Policy Brief | 10 October, 2018 | Download PDF

What is off-label use?

Off-label refers to the use of an authorised pharmaceutical product outside the terms of its marketing authorisation; therefore, not in accordance with the information in the Summary of Product Characteristics. Off-label occurs when a medicine is used for a therapeutic indication other than that approved by a regulatory authority,

Shocking Disparity Between Insulin Prices and Cost of Production

Press Release | 25 September, 2018 | Download PDF

A study published today (Tuesday 25 September) in BMJ Global Health shows that, in a global market dominated by just three multinational companies, people living with diabetes are paying far more than they should for life-saving insulin.

The paper,

Global Coalition of Health Organisations Announces First-ever International Snakebite Awareness Day

Press Release | 20 September, 2018 | Download PDF

LONDON—A coalition of organisations working on global health and tropical medicine around the world, including Health Action International, is launching the first-ever International Snakebite Awareness Day to raise awareness of the huge, yet mostly unrecognised, global impact of snakebite.

“We know,